2023-09-08 07:15:00
More quality of life, less weight
529 patients with heart failure of the HFpEF type (median age 69 years, body mass index > 30 kg/m2) took part in the one-year study and were randomly assigned to receive either weekly administration of 2.4 mg semaglutide or placebo. After a year on semaglutide, participants felt significantly better. Corresponding data on heart failure-related quality of life were collected using the Kansas Cardiomyopathy questionnaire and summarized into a score (KCCQ-CSS). Under semaglutide, the score improved by 16.6 points, significantly more than under control, in which the score only increased by 8.7 points (p < 0.001). At the same time, as expected, the test subjects in the verum group lost more weight than the controls (-13.3% vs. -2.6%; p < 0.001). In the 6-minute walk test, the distance covered was increased by 21.5 m under the active substance, while it only increased by 1.2 m under placebo (p < 0.001). Semaglutide also reduced the inflammatory parameter C-reactive protein (CRP) more significantly than placebo (-43.5% vs. -7.3%, p < 0.001).
In an exploratory analysis, the researchers evaluated how many study participants had to be hospitalized due to acute heart failure: twelve subjects from the control group and only one from the semaglutide group. A similar connection was also revealed in the analyzes of the safety of the treatment: serious adverse effects occurred significantly more frequently in the placebo group and were particularly due to cardiac events.
1694163271
#Heart #failure #symptoms #improved #study #semaglutide #weak #hearts
